Etiology and management of anemia in patients with heart failure: How much iron is missing?

Congestive Heart Failure

Volumn 14, Issue 1, 2008, Pages 25-30

  Beck da Silva, Luis ^a   Rohde, Luis E ^a   Clausell, Nadine ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON DERIVATIVE;

ANEMIA; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

ANEMIA; ERYTHROPOIETIN; HEART FAILURE; HUMANS; IRON COMPOUNDS; PREVALENCE; RISK FACTORS;

EID: 43049113575     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.07394.x     Document Type: Article

References (40)

1. Cleland JG, Khand AU, Clark AL. The heart failure epidemic: exactly how big is it? Eur Heart J. 2001;22(8):623-626.
2. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2003.
3. Rohde LE, Clausell N, Ribeiro JP, et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int J Cardiol. 2005;102(1):71-77.
4. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113(20):2454-2461.
5. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38(4):955-962.
6. Ezekowitz JA, Armstrong PW, McAlister FA. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223-225.
7. Felker GM, Shaw LK, Stough WG, et al. Anemia in patients with heart failure and preserved systolic function. Am Heart J. 2006;151(2):457-462.
8. Mozaffarian D, Levy WC, Nye R. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41(11):1933-1939.
9. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226-229.
10. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39(11):1780-1786.
11. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13(7):1928-1936.
12. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45(3):391-399.
13. Glicklich D, Kapoian T, Mian H, et al. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttrans-plantation erythrocytosis. Transplantation. 1999;68(1):62-66.
14. Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttrans-plantation erythrocytosis. J Am Soc Nephrol. 2001;12(9):1958-1964.
15. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000;2(4):393-398.
16. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoetin in congestive heart failure and correlation with clinical, hemody-namic, and hormonal profiles. Am J Cardiol. 1994;74(5):468-473.
17. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44(1):63-67.
18. Duffy TP. Microcytic and hypochromic anemias. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. Philadelphia, PA: WB Saunders; 2004: 1003-1008.
19. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80(7):1639-1647.
20. Alvarez-Hernandez X, Licéaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest. 1989;61(3):319-322.
21. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
22. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep. 1998;47(RR-3):1-29.
23. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485-2489.
24. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44(1):63-67.
25. Vaziri ND. Cardiovascular effects of eryth-ropoietin and anemia correction. Curr Opin Nephrol Hypertens. 2001;10(5):633-637.
26. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-2237.
27. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18(3):975-984.
28. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066-1076.
29. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737-1744.
30. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled trial. J Am Coll Cardiol. 2001;37(7):1775-1780.
31. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294-299.
32. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49(7):753-762.
33. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1225-1227.
34. Coletta AP, Tin L, Loh PH, et al. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur J Heart Fail. 2006;8(5):547-549.
35. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-788.
36. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22(7):1301-1307.
37. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-242.
38. Beck da Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail. 2007;13(1):14-17.
39. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226-229.
40. Ghali JK, Anand I, Abraham WT. Randomized, double-blind, placebo controlled trial to assess the impact of Darbepoetin alfa on exercise tolerance in anemic patients with symptomatic heart failure; results from the Studies of Anemia in Heart Failure Trial (STAMINA-HeFT) [abstract]. Eur J Heart Fail. 2006;5(suppl 1):122.